Part: 12         Session: 145678910111213141516171819202122         Page 861862863864865866867868869870871872873874875876877878879880881882883884885886887888889890891892893894895896897898899900901902903904905906907908909910911912913914915916917918919920921922923924925926927928929930 of 999

as efficient and Roche was ahead of them. So I understand now they're going to try to get the immune. So we'll see what happens. It's a big floating crap game.

And last year you said that there was no attempt at any coordination. There was no agency or anything.

No, trying to make it happen.

Why doesn't NIH look upon this...?

Instead of paying attention to us, you know, three years ago or four years ago, last year they began to order some Cantell type interferon, and this year they're beginning to get some Cantell type interferon, which is only one-tenth of one percent pure. However, Roche very graciously has offered them, and they have taken, some pure interferon; so now they've got a little of everything. But Dr. de Vita is worried about all this, because for him this might destroy his $125 million drug screening program. If this area things works, what he's been doing for years is going to be out of business.

So what?

So what? He doesn't like that. He's spent his life building that up. (laughs)